Method of culturing segmented filamentous bacteria in vitro
The present invention relates to an in vitro method of culturing a segmented filamentous bacterium strain, comprising co-culturing said segmented filamentous bacterium strain with a eukaryotic host cell, wherein the culture is performed at an O 2 level inferior to 5% in a rich tissue culture liquid medium containing bacterial medium components including iron. The present invention also relates to methods for genetically modifying a segmented filamentous bacterium strain comprising a step a culturing the strain in vitro.
1. A genetically modified segmented filamentous bacteria (SFB) strain expressing a foreign antigen of interest obtained from a microorganism or a cell different from a SFB.
2. The genetically modified SFB strain according to claim 1 , wherein the SFB strain is in the form of a filament, an intracellular offspring or a spore.
3. The genetically modified SFB strain according to claim 1 , wherein said foreign antigen of interest is obtained from a bacterium, a virus or a fungus organism.
4. The genetically modified SFB strain according to claim 3 , wherein said foreign antigen of interest is obtained from mainly surface proteins of the diarrheal pathogens Shigella , enterotoxic Escherichia coli (ETEC) or attaching and effacing lesion (A/E)-inducing enteropathogenic E. coli (EPEC).
5. The genetically modified SFB strain according to claim 1 , wherein said foreign antigen of interest is obtained from a tumor cell.
6. The genetically modified SFB strain according to claim 1 , wherein said foreign antigen of interest elicits a Th17 response.
7. The genetically modified SFB strain according to claim 1 , wherein the genetically modified SFB strain is obtained by co-culturing a SFB strain with a eukaryotic host cell at an O 2 level of less than 5% in a rich tissue culture liquid medium comprising bacterial medium components and iron, and wherein the co-culture is performed until the SFB strain releases intracellular offspring or spores; and by genetically transforming the SFB strain by conjugation, electroporation or chemical transformation.
8. An immunogenic composition comprising the genetically modified SFB strain according to claim 1 .
9. A method of treatment of a disease caused by a microorganism in a subject in need thereof comprising administering to said subject an effective amount of the genetically modified SFB strain of claim 1 expressing a foreign antigen of interest obtained from said microorganism.
10. The method according to claim 9 , wherein said SFB strain is administered by oral ingestion or by parenteral administration.
11. A method of treatment of a cancer in a subject in need thereof comprising administering to said subject an effective amount of the genetically modified SFB strain of claim 1 expressing a foreign antigen of interest obtained from said cancer.
12. The method according to claim 11 , wherein said SFB strain is administered by mucosal routes or by parenteral administration.